2019
Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma
Klemen ND, Wang M, Feingold PL, Cooper K, Pavri SN, Han D, Detterbeck FC, Boffa DJ, Khan SA, Olino K, Clune J, Ariyan S, Salem RR, Weiss SA, Kluger HM, Sznol M, Cha C. Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma. Journal For ImmunoTherapy Of Cancer 2019, 7: 196. PMID: 31340861, PMCID: PMC6657062, DOI: 10.1186/s40425-019-0672-3.Peer-Reviewed Original ResearchConceptsThree-year progression-free survivalProgression-free survivalDisease-specific survivalFive-year disease-specific survivalPatterns of failureDurable progression-free survivalLocal therapyStereotactic body radiotherapyMetastatic melanomaNew metastasesPatient selectionIndependent radiological reviewOngoing complete responseResultsFour hundred twentyEvidence of diseaseCNS metastasisCPI treatmentImmunotherapy failureCheckpoint inhibitorsMost patientsProgressive diseaseRadiological reviewComplete responsePD-1PD-L1
2016
Lobectomy versus stereotactic body radiotherapy in healthy patients with stage I lung cancer
Rosen JE, Salazar MC, Wang Z, Yu JB, Decker RH, Kim AW, Detterbeck FC, Boffa DJ. Lobectomy versus stereotactic body radiotherapy in healthy patients with stage I lung cancer. Journal Of Thoracic And Cardiovascular Surgery 2016, 152: 44-54.e9. PMID: 27131846, DOI: 10.1016/j.jtcvs.2016.03.060.Peer-Reviewed Original ResearchConceptsStage I lung cancerStereotactic body radiotherapyI lung cancerNational Cancer DatabaseClinical stage I lung cancerNon-small cell lung cancerCell lung cancerBody radiotherapyHealthy patientsLung cancerCancer DatabaseClinical stage I non-small cell lung cancerStage I non-small cell lung cancerBetter outcomesEarly-stage non-small cell lung cancerPatient healthCox proportional hazards modelComorbidity-free patientsClinical stage IPropensity-matched analysisProportional hazards modelLong-term survivalHealth-related reasonsStereotactic patientsT1N0M0 tumors
2012
Stereotactic Body Radiotherapy for Central Lung Tumors
Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Stereotactic Body Radiotherapy for Central Lung Tumors. Journal Of Thoracic Oncology 2012, 7: 1394-1399. PMID: 22843088, DOI: 10.1097/jto.0b013e3182614bf3.Peer-Reviewed Original ResearchConceptsStereotactic body radiotherapyCentral lung tumorsBiological equivalent doseLocal recurrenceTracheobronchial treeLung tumorsBody radiotherapyCentral lesionsEquivalent doseGrade 3Baseline pulmonary function testsLarger maximum tumor diameterMedian biological equivalent doseChest wall painGrade 3 dyspneaYale Cancer CenterGrade 2 toxicityLocal control ratePrimary lung cancerPulmonary function testsHigh-grade toxicityMajority of patientsVolume of lungMaximum tumor diameterMaximum point dose